UPB
HealthcareUpstream Bio, Inc.
$26.13
$-0.94 (-3.47%)
Jan 5, 2026
Price History (1Y)
Analysis
Upstream Bio, Inc. is a biotechnology company within the healthcare sector, with a market capitalization of $1.41B and approximately 52 employees. The company's revenue for the trailing twelve months (TTM) is $2.80M. The financial health of Upstream Bio, Inc. indicates significant losses, with a net income (TTM) of -$135,815,008 and an EBITDA of -$140,332,000. Additionally, the company's operating margin is -5539.4% and its profit margin is 0.0%. On the other hand, Upstream Bio, Inc. has a high cash balance of $372.43M and minimal debt of $1.42M. The valuation context for Upstream Bio, Inc. shows a negative P/E ratio of -8.17 and an EV/EBITDA of -7.78. The company's revenue growth rate (YoY) is 12.5%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $1.41B
- P/E Ratio
- N/A
- 52-Week High
- $33.00
- 52-Week Low
- $5.14
- Avg Volume
- 475.07K
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 52